Skip to main content
Top
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population

Authors: Li-Qiang Zhi, Wei Ma, Hong Zhang, Si-Xiang Zeng, Bo Chen

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Despite the knowledge on many genetic variants present in osteosarcoma, the complexity of this disease precludes placing its biology into a simple conceptual framework. RECQL is a DNA helicase involved in DNA mismatch repair and has been reported to be associated with many human cancers. We aimed to investigate the association of RECQL genetic polymorphism with osteosarcoma in a Chinese population. We selected three polymorphisms of the RECQL5 gene (rs820196, rs820200, and rs4789223) in the present study. TaqMan method was utilized for genotyping these three SNPs in 212 patients with osteosarcoma and 240 age- and sex-matched noncancer controls. In our study, we found that CC genotype in rs820196 (17.5 vs 8.3 %, P = 0.005) and AA genotype in rs4789223 (21.7 vs 14.2, P < 0.001) were more frequent in osteosarcoma group compared to the control group, respectively. We also found that the C allele of rs820196 (OR = 1.492, 95 % CI 1.138∼1.951; P = 0.004) and A allele of rs4789223 (OR = 1.767, 95 % CI: 1.354 ∼ 2.301; P < 0.001) were common in the osteosarcoma patients than those in the control subjects, respectively. Haplotype analysis showed that TTA (OR = 3.469, 95 % CI 1.798∼6.695; P < 0.001) was associated with increased risk for osteosarcoma. However, the TTG (OR = 0.578, 95 % CI 0.442∼0.756) was associated with decreased risk for osteosarcoma. Our results suggested that RECQL5 genetic polymorphisms were associated with osteosarcoma in a Chinese population.
Literature
2.
go back to reference Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRef
3.
go back to reference Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28:86–101.PubMedCrossRef Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28:86–101.PubMedCrossRef
4.
go back to reference Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123–32.PubMed
5.
go back to reference Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8.PubMedCrossRef
6.
go back to reference Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer. 2013. doi:10.1002/pbc.24790. Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer. 2013. doi:10.​1002/​pbc.​24790.
7.
go back to reference Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol. 2013. doi:10.1007/s13277-013-1227-8 Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1227-8
10.
go back to reference He J, Wang J, Wang D, Dai S, Yv T, Chen P, Ma R, Diao C, Lv G (2013) Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocr J. (in press). He J, Wang J, Wang D, Dai S, Yv T, Chen P, Ma R, Diao C, Lv G (2013) Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocr J. (in press).
11.
go back to reference Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics. 2010;20:507–15.PubMedCrossRef Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics. 2010;20:507–15.PubMedCrossRef
12.
go back to reference Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.PubMedCrossRef Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.PubMedCrossRef
13.
go back to reference Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.PubMedCrossRef Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.PubMedCrossRef
15.
go back to reference Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6:e26091.PubMedCentralPubMedCrossRef Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6:e26091.PubMedCentralPubMedCrossRef
16.
go back to reference Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120–2.PubMedCrossRef Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120–2.PubMedCrossRef
17.
go back to reference Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRef
18.
go back to reference O’Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet. 2006;7:45–54.PubMedCrossRef O’Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet. 2006;7:45–54.PubMedCrossRef
19.
go back to reference Sharma S, Doherty KM, Brosh RM. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J. 2006;398:319–37.PubMedCentralPubMedCrossRef Sharma S, Doherty KM, Brosh RM. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability. Biochem J. 2006;398:319–37.PubMedCentralPubMedCrossRef
22.
go back to reference Hu Y, Raynard S, Sehorn MG, Lu X, Bussen W, Zheng L, et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 2007;21:3073–84.PubMedCentralPubMedCrossRef Hu Y, Raynard S, Sehorn MG, Lu X, Bussen W, Zheng L, et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 2007;21:3073–84.PubMedCentralPubMedCrossRef
23.
go back to reference Raynard S, Bussen W, Sung P. A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. J Biol Chem. 2006;281:13861–4.PubMedCrossRef Raynard S, Bussen W, Sung P. A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. J Biol Chem. 2006;281:13861–4.PubMedCrossRef
24.
go back to reference Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.PubMedCrossRef Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.PubMedCrossRef
26.
go back to reference Pellatt AJ, Wolff RK, Lundgreen A, Cawthon R, Slattery ML. Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study. Int J Mol Epidemiol Genet. 2012;3:184–94.PubMedCentralPubMed Pellatt AJ, Wolff RK, Lundgreen A, Cawthon R, Slattery ML. Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study. Int J Mol Epidemiol Genet. 2012;3:184–94.PubMedCentralPubMed
Metadata
Title
Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population
Authors
Li-Qiang Zhi
Wei Ma
Hong Zhang
Si-Xiang Zeng
Bo Chen
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1425-4

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine